Want real case studies? 10 seconds to sign up
Join the platform
Need Regulatory Help? Try Our Platform
Post your regulatory questions or request quotations from verified pharmaceutical consultants worldwide. Get matched with experts who specialize in your market.
August 20, 2025
Approximately 5 minutes
Mastering Clinical Literature Evaluation: From PICO Frameworks to AI Automation
Literature evaluation is not just a regulatory hurdle; it is a foundational part of any Clinical Evaluation Report (CER) and Post-Market Clinical Follow-up (PMCF). As medical devices become more complex, the volume of clinical data is surging, making structured, reproducible search strategies more critical than ever.
The Structured Journey of Data Identification
A compliant literature review begins with identifying relevant clinical data through precise, Boolean-based queries. To maintain objectivity and reproducibility, regulatory professionals rely on established frameworks:
- PICO Method: Defining the Population, Intervention, Comparison, and Outcomes.
- PRISMA/MOOSE: Structured reporting methods to ensure transparency.
- Database Selection: Utilizing high-quality sources such as PubMed (NLM), Cochrane, ClinicalTrials.gov, and ScienceDirect.
Screening and Appraisal: The Core of Quality
Once results are retrieved, the focus shifts to screening based on pre-defined inclusion and exclusion criteria. Following screening, the Appraisal phase verifies that the selected data is:
- Relevant: Directly applicable to the device under evaluation.
- Valid: Scientifically and statistically sound.
- Sufficient: Providing enough volume to support conclusions.
- Unbiased: Minimally influenced by commercial or methodological conflicts.
The Role of AI in Reducing Regulatory Workload
Manual literature evaluation is notoriously time-consuming. However, emerging automation tools—validated under ISO/TR 80002-2—are transforming clinical workflows. Features like AI screening support for excluding non-human studies and agentic data extraction can reduce processing time by up to 56%. These tools provide "Audit Assurance," ensuring that critical data is not missed even beyond initial queries.
Analysis and Compliance with GSPR
With validated data in hand, the analysis must align with General Safety and Performance Requirements (GSPR) 1, 6, and 8. A clinical expert must review the findings to ensure conclusions are evidence-based and reflect the current State of the Art (SOTA). Where data gaps appear, they must be addressed through strategic PMCF planning.
Conclusion
Literature evaluation is a continuous loop. Every new SOTA assessment or PMCF update requires a fresh dive into the data. By combining rigorous scientific frameworks like PICO with modern AI automation, manufacturers can maintain high compliance standards while significantly accelerating their time to market.
Registered Pharmacist · AI Engineer · Director, ElendiLabs
Registered pharmacist, AI engineer, HKHAIS founder, and pharmaceutical & medical device SEO/GEO specialist.
Ask Anything
We'll follow up with you personally.
100% response rate • Reply within 7 business days
Related Articles
Approximately 5 minutes
Global MedTech Compliance: A Comparative Analysis of EU-MDR and UK MHRA Frameworks (2026)
An expert synthesis of the regulatory landscape in 2026, comparing the clinical-heavy requirements of EU-MDR with the pragmatic, reliance-based pathways of the UK MHRA.
Approximately 5 minutes
Master Technical Documentation under MDR 2017/745
Technical Documentation (TD) is more than just paperwork; it is the foundation of your device's identity and proof of conformity with MDR 2017/745. This article explores the 'Iceberg' of TD, breaking down the 7 essential pillars from GSPR to Post-Market Surveillance. Learn how to apply the 3Cs—Clarity, Consistency, and Connectivity—to ensure faster Notified Body reviews and a safer time to market.
Approximately 5 minutes
EUDAMED Mandatory Timeline: Essential Insights from the Brussels Workshop
With the Commission Decision 2025/2371, EUDAMED is now officially functional. The modules for Actor, Device, and Market Surveillance become mandatory on May 28, 2026. This article outlines the critical steps for manufacturers, including EU Login setup, the strict registration order, and the distinction between the Playground and Production environments.
Approximately 5 minutes
Bridging the Gap: EU vs. US Clinical Evidence Requirements for Medical Devices
Navigating the clinical evidence requirements of the EU MDR and the US FDA often catches companies off-guard. While the EU focuses on the Clinical Evaluation Report (CER) and GSPR alignment, the FDA relies on a risk-driven approach involving PMAs and 510(k) substantial equivalence. This article explores how ISO 14155 serves as a common language for both regions and highlights common weaknesses in clinical strategies that lead to regulatory rework.
Approximately 5 minutes
MDCG Guidance: Navigating the 'Best Practice' Landscape of EU MDR
The Medical Device Coordination Group (MDCG) has published over 70 guidance documents since the MDR came into force. While not legally binding legislation, these papers represent the EU Commission's 'best practice' and are used by Notified Bodies to justify audit findings. This article explores the significance of MDCG documents, their role in conformity assessments, and why manufacturers must integrate them into their compliance strategy.